about
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaOrigination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune systemInflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaSoluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of MortalitySoluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways.At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyPotentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitroExpression and function of PDCD1 at the human maternal-fetal interface.Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantationSoluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS).Assays for predicting and monitoring responses to lung cancer immunotherapy.Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression.Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis.In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade.Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.Cytokine-induced dicing and splicing in the beta-cell and the immune response in type 1 diabetes.Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay.Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients.Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis.Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia.High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
P2860
Q28088496-80B6E3C8-E0CD-4542-B128-9B4059E06300Q28740426-A95BE2EF-741A-4994-A107-D9EA7A319F4CQ33651093-1937C883-1E08-4E48-BE23-C7EA84C67622Q34245048-FA263A0E-C44A-4F9F-BE59-76893DF45D0BQ34588220-BBBEB027-304B-4CD0-91C1-75136C13A9E2Q36240333-B68DAA2D-A0B4-42E9-ADBF-E101564CB0DEQ36318396-05865ED0-49FD-4E38-9A78-73841228B639Q36935749-2EF39DCB-6BBB-482E-89D2-783C35199134Q36984486-CA1C0C3D-AAE5-48E0-BA27-058D5595D1CBQ36998864-D905E1FC-3C5E-4862-BB77-F2B03E535CB7Q37053379-3FBEA376-EC0A-4C30-A788-5356D730207CQ37208445-9305CEE3-C016-451A-87EE-76E6C2BC3418Q37391085-7641234B-8F57-4524-86EB-DB4FD2ED7840Q37410422-C36C63D6-3784-4FA9-BE22-7625BDD1E0DEQ38547391-24D804F1-FC3A-4CDD-944B-3387CE3D90CAQ38742013-9A57F496-8149-4F68-BB0F-33978E93C4C6Q38959382-B35530A8-C03D-4F10-9DC8-57AB90939BB9Q39413389-B5A786B6-7D11-4746-808C-0C735F467E87Q40184515-95E3A827-FB9B-4A04-941E-D719DE85A66DQ40185369-CEAEED20-675D-4BF6-A258-BB6B6C90C8E0Q41920188-BF248F4A-DAC8-4D00-8ECB-532B3211AE18Q41986687-1154D52C-ED95-45A4-B00C-8ACC1EF3F0C9Q42233712-1F8B31CD-E84F-4E3E-8D63-E2946912F9BFQ47134535-DE8E0245-202E-437C-9276-66D461ED2A22Q47289144-D3AB3E66-E8B7-4CA8-9C97-D4ED84BB89CDQ49176886-9CD6E209-4D29-4EB2-9A71-E4F26FEE7A97Q49309172-DF1C1872-3831-46C1-8767-8CEEECF94D1CQ50874643-CB5B0B2C-ABAD-4BFE-B1B1-4326F23CFA56Q50930412-3F8CE483-38F9-47BB-82B4-F1B6248D85C7Q54460506-6E255FC4-A930-4414-8C0A-DAED79BA5BDEQ56888862-6207C60C-D924-4009-BBA8-F5A7F32213E4
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Alternative splice variants of the human PD-1 gene
@ast
Alternative splice variants of the human PD-1 gene
@en
Alternative splice variants of the human PD-1 gene
@nl
type
label
Alternative splice variants of the human PD-1 gene
@ast
Alternative splice variants of the human PD-1 gene
@en
Alternative splice variants of the human PD-1 gene
@nl
prefLabel
Alternative splice variants of the human PD-1 gene
@ast
Alternative splice variants of the human PD-1 gene
@en
Alternative splice variants of the human PD-1 gene
@nl
P50
P3181
P1433
P1476
Alternative splice variants of the human PD-1 gene
@en
P2093
Christian Nielsen
P304
P3181
P356
10.1016/J.CELLIMM.2005.07.007
P407
P577
2005-06-01T00:00:00Z